Polymorphisms of tumor necrosis factor-α but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 44, Issue 2, 2007, Pages 171-179

  Cucchiara, Salvatore ^a   Latiano, Anna ^b   Palmieri, Orazio ^b   Canani, Roberto Berni ^c   D'Inca, Renata ^d   Guariso, Graziella ^d   Vieni, Giuseppe ^e   De Venuto, Domenica ^f   Riegler, Gabriele ^g   De'Angelis, Gian Luigi ^h   Guagnozzi, Danila ^a   Bascietto, Cinzia ^a   Miele, Erasmo ^c   Valvano, Maria Rosa ^b   Bossa, Fabrizio ^b   Annese, Vito ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c Clinica Pediatrica Università di Napoli   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h Clinica Pediatrica Università di Parma   (Italy)

Author keywords

6 Mercaptopurine; Azathioprine; Corticosteroids; Genotype phenotype; Infliximab; Medical therapy; Mesalamine; Methotrexate

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CROHN DISEASE; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE INTERACTION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STEROID THERAPY; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 33846644967     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31802c41f3     Document Type: Article

References (73)

1. Hait L, Bustards A, Grand R. Pediatric inflammatory bowel disease: what children can teach adults. Inflamm Bowel Dis 2005;11:519-27.
2. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.
3. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 2003;124:521-36.
4. Mathew CG, Lewis CM. Genetics of inflammatory bowel disease: progress and prospects. Hum Mol Genet 2004;13:161-8.
5. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
6. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
7. Economou M, Trikalinos TA, Loizou KT, et al. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a meta-analysis. Am J Gastroenterol 2004;99:2393-404.
8. Wine E, Reif SS, Leshinsky-Silver E, et al. Pediatric Crohn's disease and growth retardation: the role of genotype, phenotype, and disease severity. Pediatrics 2004;114:1281-6.
9. Kughatasan S, Collins N, Maresso K, et al. CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn's disease. Clin Gastroenterol Hepatol 2004;2:1003-9.
10. Russell RK, Drummond HE, Nimmo EE, et al. Genotype/phenotype analysis in childhood-onset Crohn's disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm Bowel Dis 2005;11:955-64.
11. Tomer G, Ceballos C, Conception E, et al. NOD2/CARD15 variants are associated with lower weight at diagnosis in children with Crohn's disease. Am J Gastroenterol 2003;98:2479-84.
12. Sun L, Roesler J, Rosen-Wolf A, et al. CARD15 genotype and phenotype analysis in 55 pediatric patients with Crohn's disease from Saxony, Germany. J Pediatr Gastroenterol Nutr 2005;37:492-7.
13. Ferraris A, Knafelz D, Torres B, et al. Analysis of CARD15 gene variants in Italian pediatric patients with inflammatory bowel diseases. J Pediatr 2005;147:272-3.
14. Roesler J, Thürigen A, Sun L, et al. Influence of CARD15 mutations on disease activity and response to therapy in 65 pediatric Crohn's patients from Saxony, Germany. J Pediatr Gastroenterol Nutr 2005;41:27-32.
15. Shaoul R, Karban A, Weiss B, et al. NOD2/CARD15 mutations and presence of granulomas in pediatric and adult Crohn's disease. Inflamm Bowel Dis 2004;10:709-14.
16. Weiss B, Shamir R, Bujanover Y, et al. NOD2/CARD15 mutation analysis and genotype-phenotype correlation in Jewish pediatric patients compared with adult with Crohn's disease. J Pediatr 2004; 145:208-12.
17. Ideström M, Rubio C, Granath F, et al. CARD15 mutations are rare in Swedish pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 2005;40:456-60.
18. Vermeire S, Rutgeerts P. Current status of genetics research in inflammatory bowel disease (IBD). Genes Immunol 2005;6: 637-45.
19. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn's disease. Nat Genet 2004;36:471-5.
20. Rioux JD, Daly MJ, Silverberg MS, et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn's disease. Nat Genet 2001;29:223-8.
21. Stoll M, Corneliussen B, Costello CM, et al. Genetic variations in DLG5 is associated with inflammatory bowel disease. Nat Genet 2004;36:476-80.
22. Trinh TT, Rioux JD. Understanding association and causality in the genetic studies on inflammatory bowel disease. Gastroenterology 2005;129:2106-10.
23. Ahmad T, Tamboli CP, Jewell D, et al. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 2004;126:1533-49.
24. Yap LM, Ahmad T, Jewell DP. The contribution of HLA genes to IBD susceptibility and phenotype. Best Pract Res Clin Gastroenterol 2004;18:577-96.
25. Levine A, Karban A, Eliakin R, et al. A polymorphism in the TNF-α is associated with pediatric onset and colonic location of Crohn's disease. Am J Gastroenterol 2005;100:407-13.
26. Levine A, Shamir R,Wine E, et al. TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn's disease. Am J Gastroenterol 2005;100:1598-604.
27. Sykora J, Subrt I, Didek P, et al. Cytokine tumor necosis factor-alpha promoter gene polymorphism at position -308G>A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease. J Pediatr Gastroenterol Nutr 2006;42:479-87.
28. Ho GT, Gaya DR, Satsangi J. Multidrug resistance (MDR1) gene in inflammatory bowel disease: a key player? Inflamm Bowel Dis 2005;11:1013-9.
29. Podolski DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
30. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of a Working Party of the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8-15.
31. Palmieri O, Latiano A, Valvano R, et al. MDR1 polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment Pharmacol Ther 2005;22:1129-38.
32. Ricart E, Taylor WR, Loftus EV, et al. N-Acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. Am J Gastroenterol 2002;97:1763-8.
33. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2.
34. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60.
35. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2002;118 (Suppl 1):S68-82.
36. Targan SR, Hanauer SB, van Deventer SJH, et al. Short-term study of chimeric monoclonal antibody ca2 to tumor necrosis factor for Crohn's disease. N Engl J Med 1997;337:1029-36.
37. Sambrook J, Fritsch EF, Maniatis F. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
38. Borruel N, Carol M, Casellas F, et al. Increased mucosal tumor necrosis factor alpha production in Crohn's disease can be down regulated ex vivo by probiotic bacteria. Gut 2002;51:659-64.
39. Komatsu M, Kobayashi D, Saito K, et al. Tumour necrosis factor-α in serum of patients with inflammatory bowel disease as measured by highly sensitive immuno PCR. Clin Chem 2001;47:1297-301.
40. Braegger CP, Nicholls S, Murch SH, et al. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
41. Breese EJ, Michie CA, Nichols SW, et al. Tumor necrosis factor alpha-producing cells in the mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-66.
42. Murch SH, Braegger CP, Walker-Smith JA, et al. Location of tumor necrosis factor-α by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;37:1705-9.
43. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B in inflammatory bowel disease. Gut 1998;42:477-84.
44. Kontoyiannis D, Pasparakis M, Pizzarro TT, et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implication for joint and gut associated immunopathologies. Immunity 1999;10:387-9.
45. Neurath MF, Fuss I, Pasparakis M, et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis mice. Eur J Immunol 1997;27:1743-50.
46. Hampe JS, Shaw SH, Saiz R, et al. Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet 1999;65:1647-55.
47. Dechairo B, Dimon C, van Heel D, et al. Replication and extension studies of inflammatory bowel disease susceptibility regions confirm linkage to chromosome 6p (IBD3). Eur J Hum Genet 2001;9:627-33.
48. Yang H, Plevy SE, Taylor D, et al. Linkage of Crohn's disease to the major histocompatibility complex region is detected by multiple non-parametric analyses. Gut 1999;44:519-26.
49. van Heel DA, Udalova IA, De Silva AP, et al. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between OCT1 and NF-κB transcription factors. Gastroenterology 2002;11:1281-9.
50. Negoro K, Kinouchi Y, Hiwatashi N, et al. Crohn's disease is associated with novel polymorphisms in the 5′-flanking region of the tumour necrosis factor gene. Gastroenterology 1999;117: 1062-8.
51. Kawasaki A, Tsuchiya N, Hagiwara K, et al. Independent contribution of HLA-DRB1 and TNF alpha promoter polymorphisms to the susceptibility to Crohn's disease. Genes Immunol 2000;1: 351-7.
52. Bouma G, Xia B, Crusisus JB, et al. Distribution of four polymorphism in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1996;103:391-6.
53. Louis E, Satsangi J, Roussomoustakaki M, et al. Cytokine gene polymorphisms in inflammatory bowel disease. Gut 1996;39:705-10.
54. Sashio H, Tamura K, Ito R, et al. Polymorphism of the TNF gene and TNF receptor superfamily 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease respectively. Immunogenetics 2002;53:1020-7.
55. Louis E, Peters M, Franchimont D, et al. Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD): influence on disease behaviour? Clin Exp Immunol 2000;119:64-8.
56. Heresbach D, Ababou A, Bourienne A. Tumor necrosis factor gene and microsatellite polymorphisms in chronic inflammatory bowel disease. Gastroenterol Clin Biol 1997;21:555-61.
57. Koss K, Satsangi J, Fanning G, et al. Cytokine (TNF-alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immunol 2000;1:185-90.
58. Plevy SE, Targan SR, Yang H, et al. Tumor necrosis factor microsatellites define a Crohn's disease-associated haplotype on chromosome 6. Gastroenterology 1996;110:1053-60.
59. Gonzalez S, Rodrigo L, Martinez-Borra J, et al. TNF-α-308A promoter polymorphism is associated with enhanced TNF-α production and inflammatory activity in Crohn's disease with fistulizing disease. Am J Gastroenterol 2003;98:1101-6.
60. Castro-Santos P, Suarez A, Lopez-Rivas L, et al. TNF-alpha and IL-10 gene polymorphisms in inflammatory bowel disease: association of - 1082 AA low producer IL-10 genotype with steroid dependency. Am J Gastroenterol 2006;101:1039-47.
61. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004;36:342-7.
62. Schinkel AH. The physiological function of drug-transporting P-glycoprotein. Semin Cancer Biol 1997;8:161-70.
63. Marzolini C, Paus E, Buclin T, et al. Polymorphism in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33.
64. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in the normal tissues. Proc Natl Acad Sci USA 1987;84:7735-8.
65. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97: 3473-8.
66. Panwala CM, Jones C, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998;161:5733-44.
67. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003;124:26-33.
68. Croucher PJ, Mascheretti S, Foelsch U, et al. Lack of association between the C3435T MDR1 gene polymorphism and inflammatory bowel disease in two independent Northern European populations. Gastroenterology 2003;125:1919-20.
69. Ho GT, Nimmo ER, Tenesa A, et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 2005;128:288-96.
70. Brant SR, Panhuysen CI, Nicolae D, et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet 2003;73:1282-92.
71. Annese V, Valvano MR, Palmieri O, et al. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J Gastroenterol 2006;12:3636-44.
72. Hattersley AT, McCarthy MI. What makes a good genetic association study? Lancet 2005;366:1315-23.
73. Ho GT, Soranzo N, Nimmo ER, et al. ABCB1/MDT1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Gen 2006;15:707-805.